Please assess the completion status of the following clinical trial:

Trial Title: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Males and Females at least 18 years of age~* Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery~* ECOG Performance status of 0 or 1~* Available tumor sample for testing~* Acceptable blood work~Exclusion Criteria:~* Primitive peritoneal, pericardial and tunica vaginalis testis mesotheliomas~* Prior chemotherapy for pleural mesothelioma~* Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 oranti-CTLA-4 antibody~* History of other malignancy unless the subject has been disease-free for at least 3 years~* Active, untreated central nervous system (CNS) metastasis~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab and Ipilimumab (Type: EXPERIMENTAL): Specified dose on specified days
- Pemetrexed and Cisplatin (or Carboplatin) (Type: ACTIVE_COMPARATOR): Specified dose on specified days

Based on this trial design, predict the completion outcome and termination type (if applicable).